Please check your internet connection and try again.
# Ticagrelor (Brilinta)
## Overview
Ticagrelor is a direct-acting, reversible P2Y12 platelet inhibitor. It is used to reduce the rate of cardiovascular events in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI).
## Primary Indications
* Reduction of thrombotic cardiovascular events (including myocardial infarction and stroke) in patients with acute coronary syndrome (ACS).
* Prevention of thrombotic events in patients with a history of myocardial infarction (MI) with evidence of high-risk characteristics.
## Adult Dosing
* **ACS:** Loading dose of 180 mg orally once, followed by 90 mg orally twice daily for up to 12 months.
* **History of MI (high-risk):** 90 mg orally twice daily. Duration of treatment should be individualized based on patient risk factors and tolerance.
* **Note:** In patients with ACS, ticagrelor should be initiated as soon as possible after symptom onset, regardless of whether percutaneous coronary intervention (PCI) is planned. For patients with a history of MI, therapy can be initiated at any time.
## Pediatric Dosing
There is no established pediatric dosing for ticagrelor.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. No dose adjustment is recommended for mild to moderate hepatic impairment. Data in severe hepatic impairment is limited.
* **Renal Impairment:** No dose adjustment is recommended for mild to moderate renal impairment. Use with caution in severe renal impairment due to limited data.
## Contraindications
* Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, nefazodone).
* Active pathological bleeding.
* Known history of transient ischemic attack (TIA) or stroke (this was a prior contraindication in some older guidelines, but current indication allows use in patients with prior stroke/TIA if they have ACS or are high-risk post-MI).
## Adverse Effects
* **Most Common:** Bleeding (including fatal and serious bleeding), dyspnea, bradyarrhythmia.
* **Serious:** Intracranial hemorrhage, gastrointestinal bleeding, surgical bleeding, ventricular dysfunction.
* **Other:** Hypotension, atrial fibrillation.
## Key Drug Interactions
* **CYP3A4 Substrates:** Ticagrelor is a moderate inhibitor of CYP3A4. Concomitant use with CYP3A4 substrates may increase exposure to those drugs (e.g., simvastatin, atorvastatin).
* **CYP3A4 Inducers:** Co-administration with strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin) may decrease ticagrelor exposure and efficacy.
* **Other Antiplatelets/Anticoagulants:** Increased risk of bleeding.
* **Proton Pump Inhibitors (PPIs):** Some evidence suggests a potential interaction with omeprazole and esomeprazole, possibly reducing ticagrelor exposure. Consider pantoprazole or ranitidine if acid suppression is needed.
## Monitoring
* **Bleeding:** Monitor for signs and symptoms of bleeding.
* **Renal and Hepatic Function:** Monitor periodically, especially in patients with impaired function.
* **Heart Rate:** Monitor for bradycardia.
## Clinical Pearls
* Ticagrelor is dosed twice daily, which is different from other P2Y12 inhibitors like clopidogrel and prasugrel.
* The most common side effect is dyspnea, which is usually mild and does not require discontinuation.
* Discontinuation of ticagrelor increases the risk of thrombotic events. If treatment must be interrupted, restart as soon as possible.
* There is no need to load with aspirin when starting ticagrelor; however, aspirin is recommended for long-term therapy in ACS patients. The optimal duration of aspirin therapy should be individualized.
* Ticagrelor should generally be stopped 5-7 days before elective surgery to reduce bleeding risk, but the decision to stop should be weighed against the risk of stent thrombosis.
***
*This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and relevant guidelines for complete details before making any treatment decisions.*
